Processa Pharmaceuticals, Inc. (PCSA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 50K 100K 150K Q1 '12: 14.6K Q2 '12: 97K Q3 '12: 49.1K Q4 '12: 31.5K Q1 '13: 19.2K Q2 '13: 97.3K Q3 '13: 125.9K Q4 '13: 70.1K Q1 '14: 20.4K Q2 '14: 112.8K Q3 '14: 52.6K Q4 '14: 50 Q1 '15: 37.8K Q2 '15: 20K Q3 '15: 58.2K Q4 '15: 17.5K Q1 '16: 5K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q1 '12 Q1 '13 Q1 '14 Q1 '15 Q1 '16 Q3 '21 Q3 '22 Q3 '23

Gross Profit Quarterly

-20K 0 20K 40K 60K Q1 '12: 2.2K Q2 '12: 43.2K Q3 '12: 15.1K Q4 '12: -1.7K Q1 '13: 7.1K Q2 '13: 35.8K Q3 '13: 45.5K Q4 '13: 36.2K Q1 '14: 11.2K Q2 '14: 42.6K Q3 '14: 27.3K Q1 '15: 12.8K Q2 '15: 9K Q3 '15: 15.5K Q1 '16: 5K Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q3 '12 Q2 '13 Q1 '14 Q1 '15 Q1 '16 Q4 '16

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '17: -233.9K Q2 '17: -280.3K Q3 '17: -712.9K Q4 '17: -575.3K Q1 '18: -1.3M Q2 '18: -1.4M Q3 '18: -1.1M Q4 '18: -741.9K Q1 '19: -882.5K Q2 '19: -1.1M Q3 '19: -1M Q4 '19: -912K Q1 '20: -986.1K Q2 '20: -802K Q3 '20: -3M Q4 '20: -10.4M Q1 '21: -2.2M Q2 '21: -3.5M Q3 '21: -3.1M Q4 '21: -3.4M Q1 '22: -3.2M Q2 '22: -5.2M Q3 '22: -6.1M Q4 '22: -13.1M Q1 '23: -4.1M Q2 '23: -2.7M Q3 '23: -2.2M Q4 '23: -2.5M Q1 '24: -2.8M Q2 '24: -3.1M Q3 '24: -3.4M Q4 '24: -2.7M Q1 '25: -2.8M Q2 '25: -4M Q3 '25: -3.5M Q4 '25: -3.7M Q1 '26: -3.3M Q2 '26: -2.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '16: -68.3K Q4 '16: -234.3K Q1 '17: -232.4K Q2 '17: -278.4K Q3 '17: -711.6K Q4 '17: -633.9K Q1 '18: -1.1M Q2 '18: -1.2M Q3 '18: -852.8K Q4 '18: -609.2K Q1 '19: -750.8K Q2 '19: -969.1K Q3 '19: -863.5K Q4 '19: -774.4K Q1 '20: -874.3K Q2 '20: -733.4K Q3 '20: -3.1M Q4 '20: -9.7M Q1 '21: -2.1M Q2 '21: -3.2M Q3 '21: -3M Q4 '21: -3.2M Q1 '22: -3.2M Q2 '22: -5.2M Q3 '22: -6M Q4 '22: -13M Q1 '23: -4M Q2 '23: -2.6M Q3 '23: -2.1M Q4 '23: -2.4M Q1 '24: -2.7M Q2 '24: -3M Q3 '24: -3.4M Q4 '24: -2.7M Q1 '25: -2.8M Q2 '25: -3.9M Q3 '25: -3.4M Q4 '25: -3.4M Q1 '26: -3.4M Q2 '26: -3.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '16: 16.7K Q4 '16: -2.1M Q1 '17: -58.7K Q2 '17: -297.2K Q3 '17: -622.9K Q4 '17: -675.8K Q1 '18: -1.1M Q2 '18: -1.2M Q3 '18: -1M Q4 '18: -464K Q1 '19: -607.4K Q2 '19: -807.5K Q3 '19: -721.8K Q4 '19: -613.5K Q1 '20: -546.5K Q2 '20: -350.6K Q3 '20: 29.2K Q4 '20: -2.3M Q1 '21: -2.2M Q2 '21: -2.2M Q3 '21: -1.6M Q4 '21: -2.7M Q1 '22: -1.8M Q2 '22: -2.3M Q3 '22: -3M Q4 '22: -2.5M Q1 '23: -2.1M Q2 '23: -2.1M Q3 '23: -1.8M Q4 '23: -2.1M Q1 '24: -2M Q2 '24: -3.3M Q3 '24: -3.6M Q4 '24: -2.2M Q1 '25: -2.7M Q2 '25: -2.3M Q3 '25: -3.5M Q4 '25: -2.9M Q1 '26: -3.6M Q2 '26: -2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '12: -900.5K Q4 '12: -662.2K Q1 '13: -599.2K Q2 '13: -775K Q3 '13: -813.2K Q4 '13: -468.5K Q1 '14: -1M Q2 '14: -710.1K Q3 '14: -550.2K Q1 '15: -503.5K Q2 '15: -276.5K Q3 '15: -47.2K Q4 '15: -46.1K Q1 '17: -59.6K Q2 '17: -297.2K Q4 '23: -2.1M Q4 '24: -2.2M Q4 '12 Q3 '13 Q2 '14 Q2 '15 Q1 '17 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '21: 14.6M Q2 '21: 15.4M Q3 '21: 15.5M Q1 '22: 15.8M Q2 '22: 15.9M Q3 '22: 16.2M Q1 '23: 1.1M Q2 '23: 1.3M Q3 '23: 1.4M Q1 '24: 2.5M Q2 '24: 3M Q3 '24: 3.3M Q1 '25: 374K Q2 '25: 628.8K Q3 '25: 47.5M Q1 '26: 2.6M Q2 '26: 2.8M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q3 '16: -0.07 Q4 '16: -0.04 Q1 '17: -0.04 Q2 '17: -0.04 Q3 '17: -0.05 Q4 '17: -0.06 Q1 '18: -0.08 Q2 '18: -0.10 Q3 '18: -0.10 Q4 '18: -0.70 Q1 '19: -0.81 Q2 '19: -0.96 Q3 '19: -1.10 Q4 '19: -0.71 Q1 '20: -0.73 Q2 '20: -0.68 Q3 '20: -1.07 Q4 '20: -2.54 Q1 '21: -2.52 Q2 '21: -2.59 Q3 '21: -2.23 Q4 '21: -0.74 Q1 '22: -0.80 Q2 '22: -0.92 Q3 '22: -1.10 Q4 '22: -34.04 Q1 '23: -37.37 Q2 '23: -38.99 Q3 '23: -40.16 Q4 '23: -8.68 Q1 '24: -6.26 Q2 '24: -5.33 Q3 '24: -4.82 Q4 '24: -96.80 Q1 '25: -103.27 Q2 '25: -108.52 Q3 '25: -107.56 Q4 '25: -10.36 Q1 '26: -4.07 Q2 '26: 1.00 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.